What SAH Is and Why the H₂+Mg Combination Changes the Equation

Aneurysmal subarachnoid hemorrhage is a catastrophic event. When an aneurysm (weakened dilation of a cerebral artery) ruptures, it can release 20–300 mL of blood into the subarachnoid space in seconds.

What happens next is a destructive cascade:

  1. 01Mechanical impact: massive pressure on cerebral tissue, trauma damage
  2. 02Initial ischemia: blood coagulates, occludes vessels, reduces blood flow
  3. 03Explosive oxidative stress: when blood comes into contact with tissue, hemoglobin is released, catalyzing massive production of free radicals. Literally an explosion of ROS
  4. 04Delayed vasospasm: 3–14 days post-event, cerebral arteries clamp down on themselves. Mechanism not fully understood, but involves inflammation, endothelin, oxidative stress

Result: catastrophic neurological damage.

Current treatment includes: surgical repair of the aneurysm, intracranial pressure management, vasodilators (such as nimodipine). But this is not enough.

Here enters the H₂+Mg protocol:

H₂ via IV acts systemically: it reduces explosive ROS post-hemorrhage. Mitochondria in the diseased brain are protected. Inflammation is modulated.

Intracisternal MgSO4 acts locally in cerebrospinal fluid: magnesium is a natural calcium-channel blocker. Calcium is critical in vasospasm. By blocking its entry, vascular spasm is prevented.

It is elegant logic: two damage mechanisms, two complementary interventions.

The Protocol: Detailed Design and Scientific Justification

Published in BMC Neurology (2014) by Takeuchi et al., the protocol specifies:

Population: Patients with severe aneurysmal SAH documented by CT (computed tomography), age >18 years, <72 hours since stroke

Intervention: Group 1: H₂ IV solution (H₂-enriched water formulation) initiated within 24h post-rupture, continued for 7 days. Dose: 50 mL/kg/day via slow IV. Group 2: MgSO4 intracisternal solution (direct injection into the cerebral cistern, typically via external ventricular drain), specified concentration and dosing Group 3: Combination H₂ IV + MgSO4 intracisternal Group 4: Control (standard of care without experimental intervention)

Endpoints: Primary: neurological outcome at 90 days (Glasgow Outcome Scale) Secondary: incidence of symptomatic vasospasm, mortality, cerebrospinal inflammation (CSF cytokines), markers of oxidative stress

Duration: 24 months of follow-up

Scientific Justification Behind the Protocol

Why this specific combination?

In animal models of experimental SAH, inhaled H₂ reduced infarct volume, improved neurological outcome, and reduced inflammatory microglial activity (brain immune cells).

In vasospasm studies, MgSO4 administered by multiple routes (IV, intracisternal) showed reduction in incidence and severity.

Both had never been combined in humans with SAH. The protocol represents a logical leap: if both mechanisms contribute to damage, why not attack both?

Window of opportunity: SAH is a medical emergency with a limited therapeutic window (first 24–72 hours). You need interventions that work fast. H₂ IV acts within minutes.

Importance of a Published Protocol for SAH

Here is what we want you to understand: subarachnoid hemorrhage is one of the most serious neurological diseases known. Mortality and morbidity are devastating.

The fact that world-class researchers publish a protocol saying "we are going to investigate H₂ + Mg for SAH" is a statement: the scientific community believes this approach merits systematic investigation.

It is not "maybe someday." It is "we are designing the trial now."

What You Can Expect from This Protocol

This protocol is not available outside specialized centers in Japan and potentially other countries where it was published. But its existence communicates:

1. If you suffer SAH in a hospital that participates in this protocol, you have the option of access to advanced neuroprotection.

2. The protocol was published in 2014; by the time of writing, preliminary or final results may exist. Investigate whether results have been published.

3. The H₂ + Mg approach opens the door to multiple neuroprotective combinations. This is the direction of serious neurological medicine: not a single magic bullet, but layers of protection.

For context: approximately 30,000 cases of aneurysmal SAH occur in the USA annually. If this protocol improves neurological outcome by even 10–15%, the impact is thousands of people with a better quality of life.

For those who do not have access to this clinical protocol, a complementary and accessible route is to incorporate hydrogen-rich water into daily intake; although it is not a substitute for acute hospital intervention, it can provide related antioxidant benefits in a sustained way.